Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma or serum

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Autosomal recessive hypercholesterolemia in a kindred of Syrian ancestry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genetic variants in SUSD2 are associated with the risk of ischemic heart disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. GPIHBP1 autoantibody syndrome during interferon β1a treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Importance of Lipoprotein Lipase Regulation in Atherosclerosis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. ANGPTL4 sensitizes lipoprotein lipase to PCSK3 cleavage by catalyzing its unfolding

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Small-Molecule Inhibition of the uPAR ⋅ uPA Interaction by Conformational Selection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Kazuya Miyashita
  • Isamu Fukamachi
  • Manabu Nagao
  • Tatsuro Ishida
  • Junji Kobayashi
  • Tetsuo Machida
  • Kiyomi Nakajima
  • Masami Murakami
  • Michael Ploug
  • Anne P Beigneux
  • Stephen G Young
  • Katsuyuki Nakajima
Vis graf over relationer

BACKGROUND: Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1), a glycosylphosphatidylinositol (GPI)-anchored protein of capillary endothelial cells, transports lipoprotein lipase to the capillary lumen and is essential for the lipolytic processing of triglyceride-rich lipoproteins.

OBJECTIVE: Because some GPI-anchored proteins have been detected in plasma, we tested whether GPIHBP1 is present in human blood and whether GPIHBP1 deficiency or a history of cardiovascular disease affected GPIHBP1 circulating levels.

METHODS: We developed 2 monoclonal antibodies against GPIHBP1 and used the antibodies to establish a sandwich enzyme-linked immunosorbent assay (ELISA) to measure GPIHBP1 levels in human blood.

RESULTS: The GPIHBP1 ELISA was linear in the 8 to 500 pg/mL range and allowed the quantification of GPIHBP1 in serum and in pre- and post-heparin plasma (including lipemic samples). GPIHBP1 was undetectable in the plasma of subjects with null mutations in GPIHBP1. Serum GPIHBP1 median levels were 849 pg/mL (range: 740-1014) in healthy volunteers (n = 28) and 1087 pg/mL (range: 877-1371) in patients with a history of cardiovascular or metabolic disease (n = 415). There was an extremely small inverse correlation between GPIHBP1 and triglyceride levels (r = 0.109; P < .0275). GPIHBP1 levels tended to be slightly higher in patients who had a major cardiovascular event after revascularization.

CONCLUSION: We developed an ELISA for quantifying GPIHBP1 in human blood. This assay will be useful to identify patients with GPIHBP1 deficiency and patients with GPIHBP1 autoantibodies. The potential of plasma GPIHBP1 as a biomarker for metabolic or cardiovascular disease is yet questionable but needs additional testing.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Lipidology
Vol/bind12
Udgave nummer1
Sider (fra-til)203-210
ISSN1933-2874
DOI
StatusUdgivet - 1 jan. 2018

ID: 52425513